{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:06:04Z","timestamp":1769263564175,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.jocn.2010.12.054","type":"journal-article","created":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T22:53:46Z","timestamp":1312239226000},"page":"1289-1294","source":"Crossref","is-referenced-by-count":41,"title":["Pharmacogenetic screening of carbamazepine-induced severe cutaneous allergic reactions"],"prefix":"10.1016","volume":"18","author":[{"given":"Chaichon","family":"Locharernkul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vorasuk","family":"Shotelersuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nattiya","family":"Hirankarn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2010.12.054_b0005","doi-asserted-by":"crossref","first-page":"28S","DOI":"10.1111\/1523-1747.ep12388434","article-title":"The spectrum of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a clinical classification","volume":"102","author":"Roujeau","year":"1994","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jocn.2010.12.054_b0010","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5070\/D397D8T291","article-title":"Treatment of severe drug reactions: Stevens\u2013Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome","volume":"8","author":"Ghislain","year":"2002","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jocn.2010.12.054_b0015","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","article-title":"Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis disease spectrum","volume":"102","author":"Power","year":"1995","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jocn.2010.12.054_b0020","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1097\/00006534-199809040-00014","article-title":"Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center","volume":"102","author":"McGee","year":"1998","journal-title":"Plast Reconstr Surg"},{"key":"10.1016\/j.jocn.2010.12.054_b0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis: a retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jocn.2010.12.054_b0030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1085-5629(96)80039-3","article-title":"Advances in toxic epidermal necrolysis","volume":"15","author":"Revuz","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jocn.2010.12.054_b0035","first-page":"273","article-title":"Burn center care for patients with toxic epidermal necrolysis","volume":"180","author":"Kelemen","year":"1995","journal-title":"J Am Coll Surg"},{"key":"10.1016\/j.jocn.2010.12.054_b0040","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/ACI.0b013e3283307abc","article-title":"Cutaneous symptoms in drug allergy: what have we learnt?","volume":"9","author":"Mayorga","year":"2009","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"10.1016\/j.jocn.2010.12.054_b0045","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1085-5629(96)80038-1","article-title":"Drug-induced pseudolymphoma and drug hypersensitivity syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS)","volume":"15","author":"Bocquet","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jocn.2010.12.054_b0050","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.arcped.2007.07.016","article-title":"DRESS syndrome, a drug reaction which remains bad known from paediatricians","volume":"14","author":"Autret-Leca","year":"2007","journal-title":"Arch Pediatr"},{"key":"10.1016\/j.jocn.2010.12.054_b0055","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/MD.0b013e3181a4d1a1","article-title":"Drug-induced hypersensitivity syndrome: clinical and biologic disease patterns in 24 patients","volume":"88","author":"Ben m\u2019rad","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jocn.2010.12.054_b0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archderm.126.1.43","article-title":"The incidence of erythema multiforme, Stevens\u2013Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients","volume":"126","author":"Chan","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jocn.2010.12.054_b0065","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens\u2013Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2010.12.054_b0070","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.WNL.0000156354.20227.F0","article-title":"Risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics","volume":"64","author":"Mockenhaupt","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2010.12.054_b0075","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1528-1167.2007.01022.x","article-title":"Association between HLA-B\u22171502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese","volume":"48","author":"Man","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2010.12.054_b0080","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1607-551X(09)70045-2","article-title":"Oxcarbazepine-induced Stevens\u2013Johnson syndrome: a case report","volume":"25","author":"Lin","year":"2009","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.jocn.2010.12.054_b0085","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2217\/14622416.9.11.1617","article-title":"HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens\u2013Johnson syndrome and toxic epidermal necrolysis","volume":"9","author":"Kaniwa","year":"2008","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jocn.2010.12.054_b0090","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/S0140-6736(98)05418-X","article-title":"Risk of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions","volume":"353","author":"Rzany","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2010.12.054_b0095","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2165\/00128071-200708020-00007","article-title":"Stevens\u2013Johnson syndrome due to concomitant use of lamotrigine and valproic acid","volume":"8","author":"Kocak","year":"2007","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jocn.2010.12.054_b0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"Medical genetics: a marker for Stevens\u2013Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jocn.2010.12.054_b0105","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/01.fpc.0000199500.46842.4a","article-title":"Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions","volume":"16","author":"Hung","year":"2006","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.jocn.2010.12.054_b0110","unstructured":"Chang CC, Too CL, Murad S, et al. Association of HLA-B\u22171502 with carbamazepine-induced toxic epidermal necrolysis and Stevens\u2013Johnson syndrome in Malaysian population. In Proceedings of the 7th Asian-Oceanian Epilepsy Congress, Xiamen 2008. p. 32 (abstract)."},{"key":"10.1016\/j.jocn.2010.12.054_b0115","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/j.1528-1167.2008.01719.x","article-title":"Carbamazepine and phenytoin induced Stevens\u2013Johnson syndrome is associated with HLA-B\u22171502 allele in Thai population","volume":"49","author":"Locharernkul","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2010.12.054_b0120","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1528-1167.2010.02533.x","article-title":"Association between HLA-B\u22171502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population","volume":"51","author":"Tassaneeyakul","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2010.12.054_b0125","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A marker for Stevens\u2013Johnson syndrome: ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jocn.2010.12.054_b0130","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2217\/14622416.7.6.813","article-title":"HLA-B locus in Caucasian patients with carbamazepine hypersensitivity","volume":"7","author":"Alfirevic","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jocn.2010.12.054_b0135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1528-1167.2009.02269.x","article-title":"HLA Class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions","volume":"51","author":"Ikeda","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2010.12.054_b0140","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/FPC.0b013e3282f3ef9c","article-title":"A European study of HLA-B in Stevens\u2013Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs","volume":"18","author":"Lonjou","year":"2008","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.jocn.2010.12.054_b0145","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1097\/FPC.0b013e32832c347d","article-title":"High-resolution HLA genotyping and severe cutaneous adverse reactions in lamotrigine-treated patients","volume":"19","author":"Kazeem","year":"2009","journal-title":"Pharmacogenet Genom"},{"key":"10.1016\/j.jocn.2010.12.054_b0150","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.humimm.2008.05.001","article-title":"Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies","volume":"69","author":"Solberg","year":"2008","journal-title":"Hum Immunol"},{"key":"10.1016\/j.jocn.2010.12.054_b0155","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1399-0039.2009.01237.x","article-title":"Distribution of HLA-A, -B, -Cw, and -DRB1 alleles and haplotypes in an isolated Han population in Southwest China","volume":"73","author":"Yao","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jocn.2010.12.054_b0160","unstructured":"Middleton D. International histocompatibility working group. Available at URL: http:\/\/www.allelefrequencies.net and www.ihwg.org [search 26 Jan 2009]."},{"key":"10.1016\/j.jocn.2010.12.054_b0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1046\/j.1365-2370.2003.00380.x","article-title":"HLA-B\u221715 subtypes in the population of north-eastern Thailand","volume":"30","author":"Romphruk","year":"2003","journal-title":"Eur J Immunogenet"},{"key":"10.1016\/j.jocn.2010.12.054_b0170","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1399-0039.2009.01281.x","article-title":"HLA-B\u221715 subtypes in Burmese population by sequence-based typing","volume":"74","author":"Kongmaroeng","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jocn.2010.12.054_b0175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1399-0039.2007.00982.x","article-title":"HLA-A, -B, -C, -DRB1 and -DQB1 alleles and haplotypes in the Kinh population in Vietnam","volume":"71","author":"Hoa","year":"2008","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jocn.2010.12.054_b0180","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1399-0039.2008.01178.x","article-title":"Polymorphisms of HLA genes in Western Javanese (Indonesia): close affinities to Southeast Asian populations","volume":"73","author":"Yuliwulandari","year":"2009","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.jocn.2010.12.054_b0185","unstructured":"Geer L, Terasaki PI, Gjertson DJ. HLA frequency. In: Gjertson DW, Terasaki PI, editors. HLA 1998. Lenexa: American Society for Histocompatibility and Immunogenetics 1998. p. 327\u201363."},{"key":"10.1016\/j.jocn.2010.12.054_b0190","unstructured":"FDA Alert 12\/12\/2007. Dangerous or even fatal skin reactions \u2013 Carbamazepine (marketed as Carbatrol, Equetro, Tegretol and generics) \u2013 Healthcare Professional Sheet text version. Available at URL: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124718.htm [search 26 Jan 2009]."},{"key":"10.1016\/j.jocn.2010.12.054_b0195","first-page":"15","article-title":"Association of HLA-B\u22171502 allele and carbamazepine induced severe adverse cutaneous drug reaction among Asians, a review","volume":"13","author":"Lim","year":"2008","journal-title":"Neurol Asia"},{"key":"10.1016\/j.jocn.2010.12.054_b0200","unstructured":"Farkas R. Clinical Review, Adverse Events of Carbamazepine, 2007. Available at URL: http:\/\/www.fda.gov\/cder\/foi\/nda\/2007\/016608s098,020712s029,021710_ClinRev.pdf [search 26 Jan 2009]."},{"key":"10.1016\/j.jocn.2010.12.054_b0205","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1212\/WNL.49.2.542","article-title":"Risk of serious cutaneous disorders after initiation of use of phenytoin, carbamazepine, or sodium valproate: a record linkage study","volume":"49","author":"Tennis","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2010.12.054_b0210","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/17410541.2.3.225","article-title":"HLA-B genotyping to detect carbamazepine-induced Stevens\u2013Johnson syndrome: implications for personalizing medicine","volume":"2","author":"Hung","year":"2005","journal-title":"Personalized Med"},{"key":"10.1016\/j.jocn.2010.12.054_b0215","first-page":"80","article-title":"Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests Review","volume":"19","author":"Mayorga","year":"2009","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jocn.2010.12.054_b0220","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1124\/mol.63.3.732","article-title":"Hypersensitivity reactions to carbamazepine: characterization of the specificity, phenotype, and cytokine profile of drug-specific T cell clones","volume":"63","author":"Naisbitt","year":"2003","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.jocn.2010.12.054_b0225","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/j.jaci.2006.12.617","article-title":"Generation and characterization of antigen-specific CD4+, CD8+, and CD4+CD8+ T-cell clones from patients with carbamazepine hypersensitivity","volume":"119","author":"Wu","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jocn.2010.12.054_b0230","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2006.03.005","article-title":"Activation of T cells by carbamazepine and carbamazepine metabolites","volume":"118","author":"Wu","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jocn.2010.12.054_b0235","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1212\/WNL.56.7.890","article-title":"TNF alpha promoter region gene polymorphisms in carbamazepine hypersensitive patients","volume":"56","author":"Pirmohamed","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2010.12.054_b0240","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.jaci.2007.06.017","article-title":"HLA-B\u22171502-bound peptides: implications for the pathogenesis of carbamazepine-induced Stevens\u2013Johnson syndrome","volume":"120","author":"Yang","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jocn.2010.12.054_b0245","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.immuni.2008.04.020","article-title":"Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity","volume":"28","author":"Chessman","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.jocn.2010.12.054_b0250","unstructured":"FDA Alert on 11\/24\/2008 Phenytoin (marketed as Dilantin, Phenytek and generics) and Fosphenytoin Sodium (marketed as Cerebyx and generics) \u2013 Healthcare Professional Sheet text version. Available at URL: http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm124788.htm, [search 26 Jan 2009]."},{"key":"10.1016\/j.jocn.2010.12.054_b0255","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/j.1528-1167.2010.02549.x","article-title":"HLA-B\u22171502 screening: time to clinical practice","volume":"51","author":"Locharernkul","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jocn.2010.12.054_b0260","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1373\/clinchem.2009.127894","article-title":"New testing approach in HLA genotyping helps overcome barriers in effective clinical practice","volume":"55","author":"Cheng","year":"2009","journal-title":"Clin Chem"},{"key":"10.1016\/j.jocn.2010.12.054_b0265","unstructured":"HLA Alleles associated with adverse drug reactions and methods for detecting such. Available at URL: http:\/\/www.surechem.org\/index.php?Action=document&docld...db [search 16 Jun 2010]."},{"key":"10.1016\/j.jocn.2010.12.054_b0270","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1056\/NEJMoa0803531","article-title":"Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs","volume":"360","author":"Meador","year":"2009","journal-title":"N Eng J Med"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586811001883?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586811001883?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,29]],"date-time":"2021-11-29T09:09:17Z","timestamp":1638176957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586811001883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0967586811001883"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2010.12.054","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}